In oncology, time is not simply a measure of care; it is a clinical variable – and increasingly a therapeutic challenge.

T-Therapeutics and Alethio Therapeutics – have raised $133 million and $90 million, respectively, in an impressive pair of ...

One of the things I enjoyed most about this year’s PM Society PMi Awards was the sheer breadth of the community in the room.

Patients with muscle-invasive bladder cancer can now receive NHS treatment with a regimen of MSD's Keytruda and Astellas' ...

The one-year-old start-up is the latest to receive financial backing from the UK government's £500 million Sovereign AI (SovAI) fund, and is working on a platform that "could make the design of new ...

Theramex, a London, UK-based specialty pharma company focusing on women's health, is changing hands in a deal reportedly ...

Businesses are finding that AI is a great leveller. Organisations with mature digital infrastructures can use AI to unlock ...

Novo has raised its financial guidance for 2026 on the back of rising sales of its oral weight-loss therapy Wegovy, which ...

The BioInnovation Institute (BII) has expanded a network striving to develop treatments for cardiometabolic diseases and ...

As an oncologist with more than 25 years of experience across clinical care, research, drug and device development, and ...

Boehringer Ingelheim is paying $358 million upfront to claim options on up to six antibody-drug conjugates (ADCs) and T cell engagers (TCEs) developed by China's Sino Biopharma (SBP Group), extending ...

Bayer's pharma unit has reached a "turning point" in its growth trajectory as sales of new medicines rose 6.4% in the third ...